Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.

A legfontosabb adatok

Ki végzi
Anterogen Co., Ltd.
Hol
Dél-Korea5 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
104 fő vett részt
Kezdés
2020. júl. 14.
Befejezés
2024. dec. 5.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • ALLO-ASC-DFU
  • Vehicle Sheet
A regiszteradat frissítve
2025. szeptember 22.

Ki vehet részt

Életkor
19 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 35 feltétel megnézéseKevesebb

Ki vehet részt

  • Subject is between 19 and 75 years of age
  • Subject is diagnosed with Type I or Type II diabetics
  • Diabetic foot ulcer has been more than 4 weeks but less than 52 weeks at the screening visit
  • Ulcer located in the foot and ulcer size is between 1.5~15 cm2
  • Ulcer graded 2 by Wagner grade
  • Foot ulcer extended to ligament, tendon, joint capsule, fascia, muscle and periosteum
  • Ulcer is free of necrotic debris
  • Ulcer area blood circulation meets one of the following criteria; Blood vessels around the ulcer detected by Doppler Test; Range of Ankle Brachial Index (ABI) is > 0.7 to < 1.3; Transcutaneous Oxygen Pressure (TcPO2) > 30mmHg or Toe Blood Pressure (TBP) > 40mmHg; Skin Perfusion Pressure (SPP) > 30mmHg
  • Subject is able to give written informed consent prior to study start and willing to comply with the study requirements

Ki nem vehet részt

  • Have undergone wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days
  • Is receiving oral or parenteral corticosteroids, any immunosuppressive, or cytotoxic agents with unstable dose within the last 30 days
  • Ulcer is of non-diabetic pathophysiology
  • There is gangrene in any part of the target foot ulcer
  • The longest dimension of the target foot ulcer exceeds 15 cm at the enrollment visit
  • Other wounds within 2cm of the target foot ulcer
  • The ulcer has increased or decreased in size by ≥ 30% during two weeks after the screening visit
  • Patient requiring intravenous (IV) antibiotics to treat foot wound infection at the screening and enrollment visit
  • Current evidence of active charcot on the study foot, osteomyelitis, cellulitis, or evidence of other infection including fever or purulent drainage from wound site
  • Patient with skin lesion confirmed by biopsy (when Investigator deems suspicious) and then judged by Investigator to be an etiology other than diabetic foot ulcer
  • An active malignant tumor(malignant melanoma, squamous cell carcinoma, basal cell carcinoma) on the body or skin
  • Is Human Immunodeficiency Virus (HIV) positive
  • Have a known history of allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue
  • Have a clinically relevant history of alcohol or drugs abuse at the screening visit
  • Is considered by the Investigator to have a significant disease which might impact the study
  • Have a history of malignancy within the last 5 years (except carcinoma in situ)
  • Have a glycated hemoglobin A1c (HbA1c) level of > 14%
  • Have severe renal failure with creatinine > 3.0mg/dL
  • Have severe hepatic deficiencies; Total bilirubin ≥ 1.5×upper normal limit(UNL); AST, ALT ≥ 2.0×UNL; Serum albumin < 2.0mg/dL
  • Have random blood sugar > 450mg/dL
  • Pregnant or breast-feeding
  • Is unwilling to use an acceptable method of birth control during the whole study
  • Is not able to understand the objective of the study or to comply with the study requirements
  • Is considered not suitable for the study by Investigator
  • Is currently or were enrolled in another clinical study within 60 days of screening
  • Cannot maintain off-loading process and device

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a phase III double-blind study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Diabetic Wagner grade 2 Foot Ulcer, compared to placebo therapy.

A vizsgálat 2 csoportja

  • ALLO-ASC-DFUA vizsgált kezelés

    Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells

  • Vehicle sheetPlacebo, összehasonlításként

    Hydrogel sheet without allogenic mesenchymal stem cell

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Phase 3 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers: A Randomized, Comparator-controlled, Double-blind, Parallel-group, Multi-center Study
A regiszteradat frissítve
2025. szeptember 22.